Basic Information
Jetrea
Regulatory Information
EMEA/H/C/002381
Authorised
March 13, 2013
January 17, 2013
15
January 16, 2021
Company Information
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Jetrea is indicated in adults for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Jetrea. It explains how the Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Jetrea. For practical information about using Jetrea, patients should read the package leaflet or contact their doctor or pharmacist.